Popsi Cube provides its pharmaceutical company sponsors with expertise in both clinical trial management and in IT services. This dual competency allows us to monitor phase I to IV clinical trials and develop tools which are specific to the needs ofour clients.
In addition to providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry, Popsi Cube is offering specific tailor made solutions and numerous applications in such fields as randomization, data capture, data management, or eCTMS compliant with EMEA and FDA regulations and quality guidelines to facilitate the clinical development process. In particular, we have developed an array of data capture solutions, from Digital Pen and Paper data capture, to eCRF, IVRS/IWRS and PDA/tablet PCs, allowing us to offer the technology that best matches the specificities of the study protocol.
To be able to best support the growing demands of our North American sponsors, Popsi Cube has decided to open a new affiliate in the US. The new company, Popsi Cube, Inc., is based in Philadelphia, PA. Our new location will allow us to support our growth objectives by establishing close relationships with our customers and by providing them with local, experienced management support for their projects.
The Company’s North American expansion is funded by a grant from COFACE on behalf of the French state, providing further recognition of the interest of our solutions and potential in North America.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.